產(chǎn)品描述: | Sivelestat is a potent and selective inhibitor of neutrophil elastase with IC50 of 44 nM. |
靶點(diǎn): |
SARS-CoV;Serine Protease;SARS-CoV;SerineProtease |
體內(nèi)研究: |
Administration of sivelestat attenuates pulmonary fibrosis after acute lung injury in mice. Sivelestat could attenuate sepsis-related kidney injury in rats. It blocks GAPDH/Siah1 which is a novel signaling pathway during the progression of spinal cord injury. |
細(xì)胞實(shí)驗(yàn): |
TMK-1 Gastric carcinoma cells are seeded into 96-well culture plates (5 ×103 cells/well) in RPMI containing 7% FBS, 2.0 mM L-glutamine, and 1% nonessential amino acids. Following 24-h incubation in RPMI-1640 medium with 5% FBS, the cells are incubated for 24, 48 or 72 h at 37°C in a humidified atmosphere of 5% CO2 with varied concentrations (0.1–1.0 μg/mL) of NE, or with varied concentrations (0.1–1000 μg/mL) of sivelestat or with concentrations (10 and 100 ng/mL) of anti-TGF-α antibody in the presence of 1 μg/mL NE. After incubation, 10 μL of MTT solution (5 mg/mL) is added to each well and the plates are then incubated for 3 h at 37°C. The growth medium is then replaced with 150 μL of dimethyl sulfoxide (Wako) per well and the absorbance at 540 nm is measured. |
動(dòng)物實(shí)驗(yàn): |
Animal Models: Male Sprague-Dawley rats. Formulation: Saline. Dosages: 50 or 100 mg/kg. Administration: i.p. |
參考文獻(xiàn): |
1.Li G, et al. Int J Mol Med. 2016, 38(3):767-75. 2.Huo J, et al. Neuroscience. 2016, 330:171-180. 3.Hagiwara S, et al. Inflamm Res. 2009, 58(4):198-203. 4.Wada Y, et al. Cancer Science. 2006, 97(10):1037-1043. 5.Araki Y, et al. Dig Dis Sci. 2011, 56(6):1672-81. |
溶解性: |
Ethanol:80 mg/mL (184.1 mM) H2O:<1 mg/mL DMSO:80 mg/mL (184.1 mM) |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.302 ml |
11.508 ml |
23.017 ml |
5 mM |
0.46 ml |
2.302 ml |
4.603 ml |
10 mM |
0.23 ml |
1.151 ml |
2.302 ml |
50 mM |
0.046 ml |
0.23 ml |
0.46 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。 |